Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mako Pushes Off Expectations For Bicompartmental Knee Procedure

This article was originally published in The Gray Sheet

Executive Summary

Mako Surgical has big expectations for its robotic approach to knee resurfacing in patients with moderate osteoarthritis, but the firm does not plan to pursue serious inroads into a large swath of the market for at least another year

You may also be interested in...



Mako Surgical

561 knee resurfacing procedures were performed using the company's robotic system and implants in the fourth quarter of 2009, up 34% from the third quarter and 181% from Q4 2008, Mako said in its March 8 earnings report for 2009. Also, seven new RIO robotic arm systems were installed during the quarter, bringing the total installed base to 36. Mako reported $8.9 million in revenue for the quarter, up from $1 million in the prior-year period. The company is expecting data to come out later this year on use of its products for bicompartmental knee resurfacing, which the company sees as a major market opportunity (1"The Gray Sheet" Nov. 9, 2009)

Moderna Stands Alone With Single-Antigen Approach To COVID-19 Vaccine

Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.

Topics

UsernamePublicRestriction

Register

MT028143

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel